Arterial Stiffness Intercostal Muscle Oxygenation and Aerobic-Anaerobic Capacity in Elite American Football Players

December 20, 2025 updated by: Meral Boşnak Güçlü, Gazi University

Investigation of Arterial Stiffness, Intercostal Muscle Oxygenation, Aerobic and Anaerobic Exercise Capacity in Elite American Football Players

American football has become an increasingly popular sport in Türkiye, and one of the key determinants of success in this discipline is the development of strong aerobic and anaerobic exercise capacities. Previous research has examined arterial stiffness in various athletic populations, including endurance athletes, wrestlers, badminton players, volleyball players, and soccer players. These studies highlight the importance of detailed cardiovascular and hemodynamic evaluation to identify potential risk groups and to better understand sport-specific physiological adaptations. In sports requiring prolonged physical effort, maximal oxygen uptake is a major determinant of performance, underscoring the need to assess this parameter in elite athletic populations. Although a limited number of studies have investigated aerobic and anaerobic exercise capacities in American football athletes, no research to date has evaluated arterial stiffness or intercostal muscle oxygenation in this group.

The present study aims to investigate arterial stiffness, intercostal muscle oxygenation, aerobic and anaerobic exercise capacity, and upper-extremity endurance in elite American football players compared with sedentary individuals. A cross-sectional study design will be used. Elite male athletes from the Gazi University American Football Team who volunteer to participate will be included, and their results will be compared with age- and sex-matched sedentary individuals. A total of 15 elite male athletes and 15 sedentary participants aged 18-30 years will be enrolled. All participants will undergo standardized assessments of arterial stiffness, intercostal muscle oxygenation, aerobic and anaerobic capacity, and upper-extremity endurance.

Normality of variables will be assessed using visual inspection and the Kolmogorov-Smirnov and Shapiro-Wilk tests. Descriptive statistics will be reported as means, standard deviations, and 95% confidence intervals for normally distributed variables, and medians with interquartile ranges (25th-75th percentiles) for non-normally distributed variables. Frequencies and percentages will be used for categorical data. Between-group comparisons will be conducted using the independent samples t-test for normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. Categorical variables will be analyzed using the chi-square test. A p-value of <0.05 will be considered statistically significant.

Study Overview

Detailed Description

American football is a sport that demands strength, speed, courage, teamwork, and tactical intelligence, and is played with three units-offense, defense, and special teams-over four quarters of 15 minutes each. Beyond technical and tactical training, aerobic and anaerobic power, speed, endurance, body composition, flexibility, coordination, and motor skills are fundamental contributors to performance. From a mechanical perspective, American football is classified as a moderate-dynamic, moderate-static sport, while metabolically it is predominantly anaerobic. Regular physical training plays a critical role in both the prevention and management of cardiovascular disease. Arterial stiffness is an established biomarker of vascular health and an independent determinant of cardiovascular risk. Although the term refers broadly to reduced elasticity, increased rigidity, or diminished distensibility of the arterial wall, all reflect impaired vascular compliance. Progressive arterial stiffening fosters a vicious cycle: rising aortic pressure accelerates vascular damage, promotes left ventricular hypertrophy, increases myocardial oxygen demand, and disrupts diastolic function. Research examining aortic impedance suggests that age-related increases in arterial stiffness occur more slowly in individuals who engage in lifelong regular exercise, although changes that emerge later in life may be irreversible.

Acute aerobic exercise has been shown to transiently improve arterial compliance, with increases of up to 30-40%, returning to baseline approximately one hour after exercise due to enhanced vasodilation. Studies evaluating athletes' brachial and central blood pressure and pulse wave velocity indicate that high-performance sport does not adversely affect arterial stiffness, and proposed reference values may support more detailed cardiovascular and hemodynamic assessment in elite athletic populations. Notably, no studies have specifically examined arterial stiffness in elite American football players. Based on existing evidence, it is anticipated that these athletes will exhibit lower arterial stiffness than sedentary individuals, suggesting reduced cardiovascular risk-a finding that may help identify at-risk groups more accurately.

Assessment of muscle oxygen metabolism in athletes is also crucial. During high-intensity competition, increased ventilatory demand can reduce blood flow to locomotor muscles, contributing to exercise intolerance and premature fatigue. Intercostal muscle oxygenation has been shown to be closely associated with peak oxygen uptake in athletes. As ventilation increases, the metabolic cost of breathing and oxygen consumption rise, elevating the respiratory muscles' oxygen requirements. The ability to adequately deliver oxygen to these muscles is therefore functionally important and merits investigation. However, no studies to date have evaluated intercostal muscle oxygenation in American football players.

Although several studies have explored physical and physiological characteristics across various sports, research specifically examining athletes engaged in American football-particularly in Türkiye, where the sport is expanding at the university level-remains limited. In prolonged athletic activity, maximal oxygen uptake (VO₂max) is a critical determinant of performance, reflecting the capacity to transport oxygen from inspired air to skeletal muscle mitochondria. At exercise intensities beyond the point at which cardiac output plateaus, the respiratory system must work disproportionately harder to maintain oxygen delivery to active tissues. VO₂max fundamentally represents the oxidative capacity of skeletal muscle mitochondria; higher values support the ability to sustain exercise for longer durations under stable physiological conditions. Aerobic capacity therefore depends on the integrated function of pulmonary, cardiovascular, hematologic, and muscular oxidative systems.

Anaerobic performance also plays a key role in sports requiring high-intensity, short-duration exertion. Energy for such activities is provided primarily through phosphagen and glycolytic pathways, which generate ATP rapidly but in limited quantities, whereas aerobic metabolism produces ATP at a slower rate but with virtually unlimited capacity. The phosphagen system supports explosive movements lasting up to approximately 15 seconds; activities lasting 15-30 seconds rely on both phosphagen and glycolytic pathways; and efforts of around 30 seconds depend almost entirely on glycolysis. Anaerobic performance varies according to individual and environmental factors, but regular training enhances these systems significantly. Athletes with higher anaerobic capacities typically exhibit greater fast-twitch muscle fiber content, larger muscle cross-sectional area, and superior muscle strength-factors that contribute to essential performance attributes such as sprinting and explosive lower-limb force.

Despite the central role of these physiological determinants, no research has examined arterial stiffness in elite American football players, and studies evaluating intercostal muscle oxygenation as well as aerobic and anaerobic capacities in this population are scarce. Therefore, the present study aims to evaluate arterial stiffness, intercostal muscle oxygenation, and aerobic and anaerobic exercise capacity in elite American football players and to compare these outcomes with those of sedentary individuals.

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Çankaya
      • Ankara, Çankaya, Turkey (Türkiye), 06490
        • Gazi University Faculty of Health Sciences Department of Cardiopulmonary Physiotherapy and Rehabilitation, Ankara, Çankaya 06490

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Thirty participants, including 15 American football players and 15 healthy controls, were evaluated.

Description

Inclusion criteria for the elite American football group :

  • Being a male athlete aged 18-30 years
  • Volunteering to participate

Exclusion criteria for the elite American football group:

  • Having any acute infection, orthopedic, neurological, or sensory problems (hearing, vision, or cooperation difficulties) that could interfere with measurements
  • A history of smoking
  • A history of alcohol consumption
  • A history of COVID-19 infection
  • Use of medications or antioxidant supplements

Inclusion criteria for the sedentary group

  • Being a male aged 18-30 years
  • Volunteering to participate

Exclusion criteria for the sedentary group

  • Included any acute, orthopedic, neurological, or sensory condition that might interfere with the assessments
  • Having a regular exercise habit

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Elite male American football players
Demographic characteristics were recorded. Inclusion criteria for the elite American football group were being a male athlete aged 18-30 years and volunteering to participate. Exclusion criteria included having any acute infection, orthopedic, neurological, or sensory problems (hearing, vision, or cooperation difficulties) that could interfere with measurements, a history of smoking, alcohol consumption, or COVID-19 infection, and use of medications or antioxidant supplements. Aerobic exercise capacity was evaluated using the Incremental Shuttle Walking Test (ISWT), anaerobic exercise capacity with the Vertical Jump Test, arterial stiffness using the SphygmoCor® XCEL Pulse Wave Analysis (PWA) Arteriograph, and intercostal muscle oxygenation by the Moxy® Muscle Oxygen Monitor.
Health Controls
Demographic characteristics were recorded. The sedentary group (sedentary individuals were defined as those engaging in less than 150 minutes per week of moderate-intensity physical activity or its equivalent, according to WHO guidelines, inclusion criteria were being a male aged 18-30 years and volunteering to participate, while exclusion criteria included any acute, orthopedic, neurological, or sensory condition that might interfere with the assessments, as well as having a regular exercise habit. Aerobic exercise capacity was evaluated using Incremental Shuttle Walking Test (ISWT), anaerobic exercise capacity with the Vertical Jump Test, arterial stiffness using the SphygmoCor® XCEL Pulse Wave Analysis (PWA) Arteriograph, and intercostal muscle oxygenation by the Moxy® Muscle Oxygen Monitor.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Arterial stiffness
Time Frame: First Day
Arterial stiffness was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters. The device provided measures of aortic systolic blood pressure (SBP), aortic pulse pressure (APP), augmentation pressure (AP), augmentation index (AIx), heart rate-corrected augmentation index (AIx@75), aortic diastolic pressure (DBP), mean arterial pressure (MAP), heart rate (HR), and ejection duration (ED).
First Day
Aortic systolic blood pressure (SBP)
Time Frame: First Day
Aortic systolic blood pressure (SBP) was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Aortic pulse pressure (APP)
Time Frame: First Day
Aortic pulse pressure (APP)was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Augmentation pressure (AP)
Time Frame: First Day
Augmentation pressure (AP) was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Heart rate-corrected augmentation index (AIx@75)
Time Frame: First Day
Heart rate-corrected augmentation index (AIx@75) was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Aortic diastolic pressure (DBP)
Time Frame: First Day
Aortic diastolic pressure (DBP) was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Mean arterial pressure (MAP)
Time Frame: First Day
Arterial stiffness was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Heart rate (HR)
Time Frame: First Day
Heart rate (HR) was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Ejection duration (ED)
Time Frame: First Day
Ejection duration (ED) was assessed noninvasively using the SphygmoCor XCEL® system (AtCor Medical, Sydney, Australia), a device with established validity and reliability for evaluating central hemodynamic parameters.
First Day
Muscle oxygenation
Time Frame: First Day
Muscle oxygenation was assessed using the Moxy® Monitor (Fortiori Design LLC, Minnesota, USA), a small, lightweight, and wireless near-infrared spectroscopy (NIRS) device that measures local muscle oxygen saturation (SmO₂) and total hemoglobin (THb) in the capillary bed of the underlying muscle tissue.
First Day
Aerobic exercise capacity
Time Frame: First day
Maximal exercise capacity was evaluated using the ISWT, a standardized, externally paced, symptom-limited field test that progressively increases walking speed at one-minute intervals.
First day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anaerobic exercise capacity
Time Frame: First day
Anaerobic capacity was assessed using the Vertical Jump Test (VJT), a valid and practical field-based method for evaluating lower-limb power and anaerobic performance. The test was performed on a flat, non-slip surface under standardized conditions. Participants stood upright with feet shoulder-width apart and arms fully extended overhead to determine standing reach height. Subsequently, a maximal countermovement jump was performed by rapidly flexing the knees and explosively extending the lower extremities, without using the arms for assistance. Jump reach height was recorded, and vertical jump height was calculated as the difference between standing reach and jump reach. The test was repeated 3-5 times with adequate rest between trials to minimize fatigue, and the highest jump was used for analysis.
First day
Anaerobic power
Time Frame: First day
Anaerobic power was assessed using a vertical jump test and calculated with a validated formula based on jump height and body mass. Participants performed maximal countermovement vertical jumps following a standardized warm-up. Hands were kept on the hips to minimize upper-extremity contribution. Jump height was measured using a validated system, and the highest value obtained was used for analysis. Anaerobic power (W) was calculated as √(4.9 × body mass [kg]) × √(jump height [m]). This method provides an indirect but reliable estimation of lower-extremity anaerobic power and reflects the ability to generate high power output during short-duration explosive movements.
First day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Meral Boşnak Güçlü, Prof, Gazi University
  • Study Chair: Betül YOLERİ, MSc, Gazi University
  • Principal Investigator: Neslişah Tunçay, Pt, Gazi University
  • Principal Investigator: Aleyna Gökdeniz, Pt, Gazi University
  • Principal Investigator: Bünyamin Ertuş, Pt, Gazi University
  • Principal Investigator: Esin Yağmur Kart, Pt, Gazi University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2024

Primary Completion (Actual)

June 1, 2025

Study Completion (Actual)

July 1, 2025

Study Registration Dates

First Submitted

December 8, 2025

First Submitted That Met QC Criteria

December 20, 2025

First Posted (Actual)

January 6, 2026

Study Record Updates

Last Update Posted (Actual)

January 6, 2026

Last Update Submitted That Met QC Criteria

December 20, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arterial Stiffness

Subscribe